StratDeckGILD

Gilead Sciences, Inc.

GILD✓
Share

Healthcare · Drug Manufacturers - General · United States

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Price146.41USD
1D+1.87%
Market cap182B
AnalystsBuy27
Next earnings29 Oct
Loading chart…

Trade ideas

  • Opinionated - ValueGood Opportunities—Paying up for qualityBuy27Board

Analysts

ConsensusBuy27
Mean score1.75
Mean target158.15+8.02%
Target range123.00–180.00

Value vs sector peers

#18 of 26 in HealthcarePaying up for quality38
  • Fwd P/E14.860
  • P/B15.49
  • Yield2.3%35
  • Rev growth+10.2%70

Not scored on P/E. The rest were reweighted to make up the difference.

Nearest in Healthcare

  1. #16ABBVAbbVie Inc.Paying up for quality41
  2. #17SYKStryker CorporationPaying up for quality41
  3. #18GILDGilead Sciences, Inc.Paying up for quality38
  4. #19MRKMerck & Co., Inc.Weakest in sector33

Fundamentals

P/E—
Forward P/E14.8
Price / book15.36
Dividend yield2.28%
Beta0.35
52-week range108.46–157.2978/100
ADV (USD)784M
Relative volume1.0
10d avg volume5.19M
Revenue growth+10.20%
EPS growth—

Performance

1D+1.87%
7D-3.04%
1M+5.82%
3M+17.79%
6M+1.49%
YTD+20.75%

In the briefing and the feed

Briefing for 11 Sept

Neither the briefing nor the research feed has named GILD.

Catalysts

Next earnings: 29 Oct

Trade idea history

No trade idea has fired on GILD since the ledger opened.

Get it by email

The board GILD sits on, in one five-minute email every weekday before the New York open and on Saturdays: market strength, the biggest movers, earnings coming up and the names sitting at their 200-day EMA.